Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Core Insights - Quoin Pharmaceuticals has reported significant progress in its clinical studies for QRX003, a treatment for Netherton Syndrome, showing almost complete skin healing and elimination of pruritus in patients [2][3] - The company has expanded its patent portfolio to support its pipeline growth, including new formulations targeting various rare skin diseases [2][8] - Quoin launched the NETHERTON NOW advocacy initiative to raise awareness and support for the Netherton community [2][6] Clinical Progress - In Q1 2025, compelling data from multiple QRX003 studies indicated substantial improvement in skin conditions for both adult and pediatric patients [2][3] - A 12-week open-label study showed sustained benefits with no safety concerns for the first adult subject treated with QRX003 [3] - Pediatric subjects demonstrated significant improvement, transitioning from "Severe" to "Mild" after six weeks of treatment [4] Patent and Pipeline Development - Quoin has filed new patents for topical rapamycin formulations and novel QRX003 formulations, potentially extending intellectual property protection through 2045 [8][9] - The company is developing new programs for microcystic lymphatic malformations, venous malformations, and angiofibromas [2] Financial Overview - As of March 31, 2025, Quoin had approximately $11.6 million in cash and equivalents, expected to support operations into Q1 2026 [10] - The company reported a net loss of approximately $3.8 million for Q1 2025, compared to a net loss of approximately $2.3 million for the same period in 2024 [11][18] Future Outlook - Quoin is advancing its clinical studies of QRX003, with new FDA-cleared studies set to evaluate whole-body application in pediatric patients [12] - The upcoming studies aim to generate extensive clinical data for Netherton Syndrome, simulating real-world use of QRX003 [12]